Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.47 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29831851 | 1.00 | CYP1A2 (0.54) | CYP1A2CYP2C19TP53ALDH1A1KDM4E | |
| SCHEMBL2921176 | 0.89 | SMN1; SMN2 (0.52) | CYP1A2CYP2C19TP53ALDH1A1KDM4E | |
| SCHEMBL30121985 | 0.89 | TP53 (0.48) | CYP1A2CYP2C19TP53ALDH1A1KDM4E | |
| SCHEMBL15075362 | 0.89 | TP53 (0.48) | CYP1A2CYP2C19TP53ALDH1A1KDM4E | |
| SCHEMBL30223258 | 0.88 | TP53 (0.47) | CYP1A2CYP2C19TP53ALDH1A1KDM4E | |
| SCHEMBL175092 | 0.88 | TP53 (0.47) | CYP1A2CYP2C19TP53ALDH1A1KDM4E | |
| SCHEMBL17611623 | 0.88 | TP53 (0.50) | CYP1A2CYP2C19TP53ALDH1A1KDM4E | |
| SCHEMBL15964663 | 0.87 | MAPT (0.48) | CYP1A2ALDH1A1KDM4EP2RY14PTGER1 | |
| SCHEMBL17610956 | 0.87 | SMN1; SMN2 (0.47) | CYP1A2CYP2C19TP53ALDH1A1KDM4E | |
| SCHEMBL17610985 | 0.87 | P2RY14 (0.50) | CYP1A2CYP2C19TP53ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3998260-B1 | SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-3998260-B1 | SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2023-11-01 | — | — | EP | disclosed |
| CN-109369635-B | Compound or pharmaceutically acceptable salt thereof, application thereof and pharmaceutical composition | 赛克里翁治疗有限公司 | 2023-06-30 | — | — | CN | disclosed |
| US-20230106002-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. | 2023-04-06 | — | — | US | disclosed |
| CN-109384778-B | Use of a compound or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of a disease, health condition or disorder | 赛克里翁治疗有限公司 | 2022-12-13 | — | — | CN | disclosed |
| CN-110016020-B | Compound or pharmaceutically acceptable salt thereof, application and pharmaceutical composition thereof | 赛克里翁治疗有限公司 | 2022-07-26 | — | — | CN | disclosed |
| EP-3998260-A1 | SGC STIMULATORS | Cyclerion Therapeutics, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
| CN-107406422-B | Pyrazole derivatives as sGC stimulators | 赛科理音医疗有限公司 | 2022-02-01 | — | — | CN | disclosed |
| EP-3660013-B1 | SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2022-01-19 | — | — | EP | disclosed |
| EP-3660013-B1 | SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2022-01-19 | — | — | EP | disclosed |
| US-9481689-B2 | sGC stimulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| WO-2016044447-A1 | PYRAZOLE DERIVATIVES AS SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| WO-2016044447-A1 | PYRAZOLE DERIVATIVES AS SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| US-20160031903-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-02-04 | — | — | US | disclosed |
| US-20160031903-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-02-04 | — | — | US | disclosed |
| US-20160031903-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-02-04 | — | — | US | disclosed |
| EP-2970243-A2 | SGC STIMULATORS | Ironwood Pharmaceuticals, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014144100-A2 | SGC STIMULATORS | NAKAI TAKASHI (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014144100-A2 | SGC STIMULATORS | NAKAI TAKASHI (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014125444-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230106002-A1 | sGC STIMULATORS | PTGIS, CGAS, GUCY1A1 | CYP1A2 872/4885CYP2C19 1024/4885TP53 4691/4885 |
| US-20160031903-A1 | sGC STIMULATORS | PTGIS, CGAS, GUCY1A1 | CYP1A2 872/4885CYP2C19 1024/4885TP53 4691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.